Indications and uses
PREHEVBRIO is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PREHEVBRIO is approved for use in adults 18 years of age and older.
PREHEVBRIO
- Manufacturer
- VBI Vaccines (Delaware) Inc. | BioReliance | SciVac Ltd | Envigo CRS (Israel) Limited | Hy-Labs | IMI TAMI Institute for Research and Development Ltd.
- Effective date
- 2024-02-22
- Label type
- VACCINE LABEL
- Version
- 6
- Source
- full-release
- Hydrated at
- 2026-06-01 02:51:01
Label at a glance#
ProductPREHEVBRIO
Active ingredientRECOMBINANT HEPATITIS B SURFACE ANTIGEN (ISOFORM S), RECOMBINANT HEPATITIS B SURFACE ANTIGEN (ISOFORM M), RECOMBINANT HEPATITIS B SURFACE ANTIGEN (ISOFORM L)
Label structure16 sections
Dosage and administration
For intramuscular injection. Administer a series of three doses (1.0 mL each) of PREHEVBRIO on a 0-, 1- and 6-month schedule. Shake the vial of PREHEVBRIO well to obtain a slightly opaque, white suspension. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If either of these conditions exists, the vaccine s...
Storage and handling
Single dose vial, 1.0 mL (NDC number 75052-001-01) Supplied as a package of 10 single dose vials (NDC number: 75052-001-10) The vial stoppers are not made with natural rubber latex. Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze ; discard if the vaccine has been frozen. Do not use the vaccine after the expiration date shown on the vial label.
Contacts and useful links#
Websitewww.vaers.hhs.gov
www.vaers.hhs.gov
www.vaers.hhs.govWebsitewww.cdc.gov
www.cdc.gov/vaccines
www.cdc.gov/vaccinesLabel contents#
Full prescribing information#
1 INDICATIONS AND USAGE
PREHEVBRIO is indicated for prevention of infection caused by all known subtypes of hepatitis B virus.
PREHEVBRIO is approved for use in adults 18 years of age and older.
2 DOSAGE AND ADMINISTRATION
For intramuscular injection.
2.1 Dosage and Schedule
Administer a series of three doses (1.0 mL each) of PREHEVBRIO on a 0-, 1- and 6-month schedule.
2.2 Administration
Shake the vial of PREHEVBRIO well to obtain a slightly opaque, white suspension.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.
Administer PREHEVBRIO by intramuscular injection.
3 DOSAGE FORMS AND STRENGTHS
PREHEVBRIO is an injectable suspension, for intramuscular use supplied as a single-dose vial. A single dose of PREHEVBRIO is 1.0 mL [see How Supplied/Storage and Handling ( 16.1)].
4 CONTRAINDICATIONS
Do not administer PREHEVBRIO to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PREHEVBRIO [see Description ( 11)].
5 WARNINGS AND PRECAUTIONS
5.1 Managing Allergic Reactions
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of PREHEVBRIO.
5.2 Immunocompromised Individuals
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to PREHEVBRIO.
5.3 Limitations of Vaccine Effectiveness
Hepatitis B has a long incubation period. PREHEVBRIO may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
6 ADVERSE REACTIONS
Individuals 18 through 44 years of age: The most common local reactions following each dose of PREHEVBRIO were injection site pain (52.0 – 58.3%) and tenderness (52.6 – 59.6%). The most common systemic reactions following each dose of PREHEVBRIO were headache (17.2 – 25.8%), fatigue (20.1- 28.3%) and myalgia (22.2 – 29.9%).
Individuals 45 through 64 years of age: The most common local reactions following each dose of PREHEVBRIO were injection site pain (42.2 – 48.8%) and tenderness (43.2 – 50.5%). The most common systemic reactions following each dose of PREHEVBRIO were headache (13.8 – 21.3%), fatigue (14.3 – 19.7%) and myalgia (16.7 – 24.1%).
Individuals ≥ 65 years of age: The most common local reactions following each dose of PREHEVBRIO were injection site pain (26.7 – 34.8%) and tenderness (30.2 – 32.8%). The most common systemic reactions following each dose of PREHEVBRIO were headache (7.3 – 12.2%), fatigue (11.5 – 14.5%) and myalgia (11.5 - 16.6%).
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.
The safety of PREHEVBRIO was evaluated in 2 active-controlled clinical studies (Studies 1 and 2) involving 4,443 subjects who received at least 1 dose of PREHEVBRIO (n = 2,920) or Engerix-B [Hepatitis B Vaccine (Recombinant)] (n = 1,523) administered according to a 0-, 1- and 6-months schedule.
SPL UNCLASSIFIED SECTION
Study 1 in adults ≥18 years of age
Study 1 was a randomized, double-blind, active-controlled, multicenter study that enrolled subjects in the United States (US), Canada, Belgium and Finland in which 796 subjects received at least 1 dose of PREHEVBRIO and 811 subjects received at least 1 dose of Engerix-B. In the total study population at baseline the mean age was 57 years, 81% were age ≥45 years; 62% were women; 90% were White, 8% Black, 1% Asian, and 10% Hispanic/Latino; 37% were obese (body mass index [BMI] >30 kg/m 2), 14% were current smokers and 8% had Type 2 diabetes mellitus. Demographic and baseline characteristics were similar in both vaccine groups.
SPL UNCLASSIFIED SECTION
Solicited Local and Systemic Adverse Reactions
Subjects were monitored for local and systemic adverse reactions using diary cards for a 7-day period starting on the day of vaccination. The percentages of subjects who reported local and systemic reactions in Study 1 are shown by age subgroup in Table 1 to Table 3.
| PREHEVBRIO Dose 1 (N=145) % | PREHEVBRIO Dose 2 (N=141) % | PREHEVBRIO Dose 3 (N= 134) % | Engerix-B Dose 1 (N=154) % | Engerix-B Dose 2 (N=152) % | Engerix-B Dose 3 (N=148) % | |
|---|---|---|---|---|---|---|
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| Local Reaction | ||||||
| Pain | 58.6 | 50.4 | 46.3 | 33.8 | 28.9 | 31.8 |
| Pain, Grade 3 or greater a | 0 | 0 | 0 | 0 | 0 | 0 |
| Tenderness | 53.8 | 50.4 | 42.5 | 32.5 | 32.2 | 36.5 |
| Tenderness, Grade 3 or greater b | 0.7 | 0 | 0.7 | 0.6 | 0.7 | 0.7 |
| Itching | 2.1 | 3.5 | 6.0 | 7.1 | 3.9 | 7.4 |
| Itching, Grade 3 or greater c | 0 | 0 | 0 | 0 | 0.7 | 1.4 |
| Redness (≥ 2.5 cm) | 0.7 | 1.4 | 1.5 | 0.6 | 1.3 | 0 |
| Redness, Grade 3 or greater d | 0 | 0 | 0 | 0 | 0 | 0 |
| Swelling (≥ 2.5 cm) | 2.8 | 1.4 | 0.7 | 0 | 1.3 | 2.0 |
| Swelling, Grade 3 or greater e | 0 | 0 | 0 | 0 | 0.7 | 1.4 |
| Systemic Reaction | ||||||
| Headache | 33.8 | 24.1 | 20.9 | 29.9 | 19.1 | 13.5 |
| Headache, Grade 3 or greater a | 1.4 | 0.7 | 0 | 1.3 | 0.7 | 0 |
| Fatigue | 29.7 | 22.0 | 22.4 | 31.8 | 20.4 | 20.3 |
| Fatigue, Grade 3 or greater c | 1.4 | 0.7 | 0 | 0.6 | 2.0 | 1.4 |
| Myalgia | 27.6 | 24.1 | 21.6 | 20.8 | 11.8 | 10.1 |
| Myalgia, Grade 3 or greater c | 0.7 | 0 | 0 | 0 | 1.3 | 0 |
| Diarrhea | 9.7 | 5.7 | 4.5 | 9.7 | 5.9 | 7.4 |
| Diarrhea, Grade 3 or greater f | 0.7 | 0 | 0 | 0 | 0.7 | 0 |
| Nausea/Vomiting | 8.3 | 4.3 | 4.5 | 7.8 | 6.6 | 6.1 |
| Nausea/Vomiting, Grade 3 or greater f | 0 | 0.7 | 0 | 0 | 0.7 | 0 |
| Fever (≥100.4°F) | 0.7 | 0.7 | 0 | 1.3 | 0 | 0.7 |
| Fever, Grade 3 or greater (≥102.1°F) | 0.7 | 0 | 0 | 0 | 0 | 0 |
| PREHEVBRIO Dose 1 (N=355) % | PREHEVBRIO Dose 2 (N=350) % | PREHEVBRIO Dose 3 (N=343) % | Engerix-B Dose 1 (N=361) % | Engerix-B Dose 2 (N=357) % | Engerix-B Dose 3 (N=349) % | |
|---|---|---|---|---|---|---|
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| Local Reaction | ||||||
| Pain | 46.8 | 44.9 | 39.4 | 22.2 | 15.4 | 17.2 |
| Pain, Grade 3 or greater a | 0 | 0 | 0.3 | 0 | 0 | 0 |
| Tenderness | 48.7 | 42.6 | 40.5 | 23.8 | 16.5 | 17.5 |
| Tenderness, Grade 3 or greater b | 0.8 | 0.6 | 0.3 | 0 | 0 | 0.3 |
| Itching | 4.5 | 3.1 | 3.8 | 3.9 | 2.0 | 3.4 |
| Itching, Grade 3 or greater c | 0 | 0.3 | 0 | 0 | 0 | 0 |
| Redness (≥ 2.5 cm) | 1.7 | 0.6 | 0.3 | 1.1 | 0.3 | 1.1 |
| Redness, Grade 3 or greater d | 0 | 0 | 0 | 0.8 | 0.3 | 0.6 |
| Swelling (≥ 2.5 cm) | 1.4 | 0.3 | 0.9 | 0 | 0.6 | 0.3 |
| Swelling, Grade 3 or greater e | 0 | 0 | 0.3 | 0 | 0 | 0 |
| Systemic Reaction | ||||||
| Headache | 21.4 | 13.7 | 15.7 | 20.5 | 11.2 | 14.0 |
| Headache, Grade 3 or greater a | 0 | 0 | 0.3 | 0.3 | 0.3 | 0.3 |
| Fatigue | 16.6 | 16.9 | 12.5 | 22.2 | 11.5 | 12.3 |
| Fatigue, Grade 3 or greater c | 0.6 | 0 | 0.3 | 0.6 | 0.3 | 0.6 |
| Myalgia | 21.4 | 20.0 | 15.5 | 16.1 | 8.4 | 9.5 |
| Myalgia, Grade 3 or greater c | 0.6 | 0 | 0 | 0 | 0 | 0 |
| Diarrhea | 4.8 | 4.0 | 3.2 | 6.4 | 3.6 | 3.7 |
| Diarrhea, Grade 3 or greater f | 0 | 0 | 0 | 0 | 0 | 0 |
| Nausea/Vomiting | 4.2 | 2.9 | 2.3 | 6.4 | 3.6 | 2.6 |
| Nausea/Vomiting, Grade 3 or greater f | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever (≥100.4°F) | 0.6 | 0 | 0 | 0.3 | 0.3 | 0.6 |
| Fever, Grade 3 or greater (≥102.1°F) | 0 | 0 | 0 | 0 | 0 | 0.3 |
| PREHEVBRIO Dose 1 (N=296) % | PREHEVBRIO Dose 2 (N=288) % | PREHEVBRIO Dose 3 (N=281) % | Engerix-B Dose 1 (N=296) % | Engerix-B Dose 2 (N=292) % | Engerix-B Dose 3 (N= 288) % | |
|---|---|---|---|---|---|---|
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| Local Reaction | ||||||
| Pain | 34.8 | 28.8 | 26.7 | 16.2 | 12.0 | 11.1 |
| Pain, Grade 3 or greater a | 0 | 0 | 0 | 0.3 | 0 | 0 |
| Tenderness | 32.8 | 30.2 | 31.0 | 14.2 | 12.0 | 10.1 |
| Tenderness, Grade 3 or greater b | 0 | 0 | 0 | 0 | 0 | 0 |
| Itching | 6.1 | 3.8 | 5.0 | 4.1 | 1.4 | 2.4 |
| Itching, Grade 3 or greater c | 0 | 0 | 0 | 0 | 0 | 0 |
| Redness (≥ 2.5 cm) | 1.0 | 0.3 | 1.4 | 0.7 | 0.3 | 0 |
| Redness, Grade 3 or greater d | 0.3 | 0 | 0.4 | 0 | 0.3 | 0 |
| Swelling (≥ 2.5 cm) | 1.0 | 0.7 | 1.1 | 1.4 | 0.3 | 0.3 |
| Swelling, Grade 3 or greater e | 0.3 | 0 | 0 | 0 | 0.3 | 0 |
| Systemic Reaction | ||||||
| Headache | 12.2 | 7.3 | 7.8 | 12.8 | 5.8 | 6.9 |
| Headache, Grade 3 or greater a | 0 | 0 | 0 | 0 | 0 | 0 |
| Fatigue | 14.5 | 11.5 | 12.5 | 17.9 | 9.9 | 10.1 |
| Fatigue, Grade 3 or greater c | 0 | 0 | 0 | 0.7 | 0 | 0.3 |
| Myalgia | 16.6 | 11.5 | 13.2 | 12.8 | 8.2 | 6.9 |
| Myalgia, Grade 3 or greater c | 0 | 0 | 0 | 0 | 0.3 | 0 |
| Diarrhea | 6.4 | 4.2 | 1.1 | 6.4 | 2.4 | 3.5 |
| Diarrhea, Grade 3 or greater f | 0.3 | 0 | 0 | 0.3 | 0 | 0 |
| Nausea/Vomiting | 3.7 | 0.7 | 1.1 | 1.7 | 1.7 | 0.7 |
| Nausea/Vomiting, Grade 3 or greater f | 0 | 0 | 0 | 0.3 | 0 | 0.3 |
| Fever (≥100.4°F) | 0 | 0 | 0.7 | 0 | 0 | 0.7 |
| Fever, Grade 3 or greater (≥102.1°F) | 0 | 0 | 0 | 0 | 0 | 0 |
The median duration of local and systemic solicited adverse reactions was 1-2 days in both treatment groups. Among all subjects who received PREHEVBRIO, the frequencies of the most commonly reported solicited reactions extending beyond the 7-day assessment period were as follows: fatigue (4.1%), injection site pain (2.0%), headache (1.9%) and myalgia (1.9%).
SPL UNCLASSIFIED SECTION
Study 2 in adults 18 through 45 years of age
Study 2 was a randomized, double-blind, active-controlled, multicenter study that enrolled subjects in the US, Canada, Belgium, Finland, Germany and the United Kingdom in which 2,124 subjects received at least 1 dose of PREHEVBRIO and 712 subjects received at least 1 dose of Engerix-B. In the total study population at baseline, the mean age was 34 years; 58% were women; 92% were White, 6% Black, 2% Asian, and 10% Hispanic/Latino; 18% were obese (BMI >30 kg/m 2) and 19% were current smokers. Demographic and baseline characteristics were similar in both vaccine groups.
SPL UNCLASSIFIED SECTION
Solicited Local and Systemic Adverse Reactions
Subjects were monitored for local and systemic adverse reactions using diary cards for a 7-day period starting on the day of vaccination. The percentages of subjects who reported local and systemic reactions in Study 2 are shown in Table 4.
| PREHEVBRIO Dose 1 (N=2122) a % | PREHEVBRIO Dose 2 (N=2071) % | PREHEVBRIO Dose 3 (N=1967) % | Engerix-B Dose 1 (N=712) % | Engerix-B Dose 2 (N=701) % | Engerix-B Dose 3 (N=671) % | |
|---|---|---|---|---|---|---|
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| Local Reaction | ||||||
| Pain | 58.2 | 52.2 | 52.5 | 35.1 | 29.2 | 32.5 |
| Pain, Grade 3 or greater b | 0.3 | 0.3 | 0.4 | 0.1 | 0 | 0.3 |
| Tenderness | 59.9 | 52.9 | 55.5 | 37.6 | 30.4 | 33.8 |
| Tenderness, Grade 3 or greater c | 0.8 | 0.9 | 0.8 | 0.6 | 0.1 | 0.1 |
| Itching | 5.7 | 5.7 | 6.7 | 6.6 | 5.3 | 5.4 |
| Itching, Grade 3 or greater d | 0 | 0 | 0.1 | 0.3 | 0.1 | 0 |
| Redness (≥ 2.5 cm) | 1.1 | 1.1 | 1.3 | 0.6 | 0.4 | 1.0 |
| Redness, Grade 3 or greater e | 0.2 | 0 | 0.2 | 0.1 | 0.1 | 0.1 |
| Swelling (≥ 2.5 cm) | 1.2 | 0.9 | 1.1 | 0.6 | 0 | 0.4 |
| Swelling, Grade 3 or greater f | 0.1 | 0 | 0.1 | 0 | 0 | 0 |
| Systemic Reaction | ||||||
| Headache | 25.1 | 16.7 | 17.4 | 24.2 | 15.0 | 18.3 |
| Headache, Grade 3 or greater b | 0.3 | 0.2 | 0.5 | 0.4 | 0.4 | 0.6 |
| Fatigue | 28.4 | 19.8 | 20.2 | 27.1 | 17.8 | 22.1 |
| Fatigue, Grade 3 or greater d | 0.5 | 0.8 | 0.6 | 0.4 | 0.6 | 0.6 |
| Myalgia | 30.3 | 21.9 | 23.6 | 17.7 | 13.0 | 18.5 |
| Myalgia, Grade 3 or greater d | 0.3 | 0.6 | 0.5 | 0.4 | 0.1 | 0.4 |
| Diarrhea | 7.4 | 5.0 | 4.4 | 9.6 | 4.9 | 5.4 |
| Diarrhea, Grade 3 or greater g | 0.2 | 0.1 | 0.1 | 0 | 0 | 0 |
| Nausea/Vomiting | 6.7 | 3.7 | 4.7 | 7.0 | 3.6 | 3.9 |
| Nausea/Vomiting, Grade 3 or greater g | 0 | 0 | 0.2 | 0 | 0.1 | 0 |
| Fever (≥100.4°F) | 0.3 | 0.3 | 0.6 | 0.4 | 0.3 | 0.9 |
| Fever, Grade 3 or greater (≥102.1°F) | 0 | 0.1 | 0.1 | 0.1 | 0 | 0 |
The median duration of local and systemic solicited adverse reactions was 1-2 days in both treatment groups. Among all subjects who received PREHEVBRIO, the frequencies of the most commonly reported solicited reactions extending beyond the 7-day assessment period were as follows: fatigue (3.5%), injection site pain (2.0%), headache (1.9%) and myalgia (1.8%).
SPL UNCLASSIFIED SECTION
Unsolicited Adverse Events (AEs)
In both studies, unsolicited adverse events, including serious and non-serious events, that occurred within 28 days following each vaccination were recorded on a diary card by all subjects.
In both studies combined, unsolicited AEs that occurred within 28 days of any vaccination were reported by 48.3% and 48.4% of subjects who received PREHEVBRIO or Engerix-B, respectively. Unsolicited AEs in subjects who received PREHEVBRIO for which available information suggests a causal relationship to vaccination include injection site bruising (1.4%), dizziness/vertigo (1.1%), general pruritus/itchiness (0.2%), arthralgia (0.2%), urticaria/hives (0.2%) and lymphadenopathy/lymph node pain (0.1%).
SPL UNCLASSIFIED SECTION
Serious Adverse Events (SAEs)
In both studies, SAEs were collected from first vaccination through 6 months following the last vaccination. In both studies combined, SAEs were reported by 0.9% and 0.6% within 28 days of vaccination with PREHEVBRIO or Engerix-B, respectively. SAEs were reported by 2.5% of subjects in the PREHEVBRIO group and 1.6% in the Engerix-B group from the first vaccination through 6 months following the third vaccination. There were no notable patterns or numerical imbalances between vaccination groups for specific categories of serious adverse events that would suggest a causal relationship to PREHEVBRIO.
7 DRUG INTERACTIONS
7.1 Concomitant Administration with Immune Globulin
There are no data to assess the concomitant use of PREHEVBRIO with immune globulin. When concomitant administration of PREHEVBRIO and immune globulin is required, they should be given with different syringes at different injection sites.
7.2 Interference with Laboratory Tests
Hepatitis B surface antigen (HBsAg) derived from hepatitis B vaccines has been transiently detected in blood samples following vaccination. Serum HBsAg detection may not have diagnostic value within 28 days after receipt of PREHEVBRIO.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
SPL UNCLASSIFIED SECTION
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to PREHEVBRIO during pregnancy. Women who receive PREHEVBRIO during pregnancy are encouraged to contact 1-888-421-8808 (toll-free).
SPL UNCLASSIFIED SECTION
Risk Summary
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In clinically recognized pregnancies in the US general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20%.
There are no adequate and well-controlled studies of PREHEVBRIO in pregnant women. Available human data on PREHEVBRIO administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.
A developmental toxicity study has been performed in female rats administered the equivalent of a single human dose of PREHEVBRIO on four occasions; twice prior to mating, twice during gestation. The study revealed no evidence of harm to the fetus due to the vaccine [see Animal Data below].
SPL UNCLASSIFIED SECTION
Data
SPL UNCLASSIFIED SECTION
Animal Data
A developmental toxicity study has been performed in female rats using a dose equivalent to the adult human dose. In the study, female rats received 0.5 mL (2 x 0.25 mL injections) of a vaccine formulation containing 10 mcg HBsAg (S, pre-S1, pre-S2) adsorbed on to aluminum hydroxide by intramuscular injection 30 days and 15 days prior to mating and on gestation days 4 and 15. No adverse effects of pre-weaning development were observed. There was no evidence of fetal malformations or variations.
8.2 Lactation
SPL UNCLASSIFIED SECTION
Risk Summary
It is not known whether PREHEVBRIO is excreted in human milk. Data are not available to assess the effects of PREHEVBRIO on the breastfed infant or on milk production/excretion.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PREHEVBRIO and any potential adverse effects on the breastfed child from PREHEVBRIO or from the underlying maternal condition. For preventive vaccines, the underlying condition is susceptibility to disease prevented by the vaccine.
8.4 Pediatric Use
Safety and effectiveness of PREHEVBRIO have not been established in individuals less than 18 years of age.
8.5 Geriatric Use
Study 1 included 296 adults 65 through 86 years of age who received PREHEVBRIO. Among subjects who received PREHEVBRIO, a seroprotective level of antibody to HBsAg was achieved in 83.6% of those ≥ 65 years of age compared to 94.8% in adults 45 through 64 years of age and 99.2% in adults 18 through 44 years of age [see Evaluation of Immunogenicity ( 14.1)].
Frequencies of local and systemic solicited adverse reactions were generally lower in elderly subjects ≥65 years of age than in younger subjects [see Adverse Reactions ( 6)].
8.6 Adults on Hemodialysis
Safety and effectiveness of PREHEVBRIO have not been established in adults on hemodialysis.
11 DESCRIPTION
PREHEVBRIO [Hepatitis B Vaccine (Recombinant)] is a sterile suspension for intramuscular injection.
PREHEVBRIO contains the small (S), middle (pre-S2) and large (pre-S1) hepatitis B surface antigens, co-purified from genetically modified CHO (Chinese Hamster Ovary) cells cultured in growth medium containing vitamins, amino acids, minerals, and fetal bovine serum.
The hepatitis B surface antigens are co-purified from the supernatant of CHO cells by a series of physicochemical steps as virus-like particles containing CHO cell membrane lipids.
Each 1.0 mL dose is formulated to contain 10 mcg hepatitis B surface antigens (S, pre-S1 and pre-S2) adsorbed on aluminum hydroxide [Al(OH) 3] as an adjuvant (aluminum content of 0.5 mg/mL).
Each 1.0 mL dose of PREHEVBRIO also contains sodium chloride (NaCl) (8.45 mg/dose), potassium chloride (KCl) (0.02 mg/dose), disodium hydrogen phosphate dodecahydrate (Na 2HPO 4.12H 2O) (0.38 mg/dose), potassium dihydrogen phosphate anhydrous (KH 2PO 4) (0.02 mg/dose) and water for injections (WFI). Each dose may contain residual amounts of CHO cell proteins (up to 2.5 ng/dose), CHO cell DNA (up to 10 pg/dose), Bovine Serum Albumin (up to 2.5 ng/dose) and Formaldehyde (up to 500 ng/dose) from the manufacturing process.
PREHEVBRIO does not contain a preservative.
The vial stoppers are not made with natural rubber latex.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
PREHEVBRIO induces antibodies to HBsAg. Antibody concentrations ≥10 mIU/mL against HBsAg are recognized as conferring protection against hepatitis B virus infection.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
PREHEVBRIO has not been evaluated for carcinogenic, mutagenic potential or male infertility in animals. In a developmental toxicity study in rats with a vaccine formulation containing 10 mcg HBsAg (S, pre-S1, pre-S2) adsorbed on to aluminum hydroxide there were no effects on female fertility [see Animal Data ( 8.1)].
14 CLINICAL STUDIES
14.1 Evaluation of Immunogenicity
The immunogenicity of PREHEVBRIO was evaluated in comparison with a US-licensed hepatitis B vaccine (Engerix-B) in 2 randomized, active controlled, double-blind, multi-center Phase 3 clinical trials in adults. PREHEVBRIO and Engerix-B were administered according to a 0-, 1- and 6-month schedule. For subject baseline characteristics, see section 6.1.
The trials compared the seroprotection rates (SPR), defined as the proportion of participants with anti-HBs titers ≥ 10 mIU/mL, induced by PREHEVBRIO and Engerix-B. Non-inferiority was met if the lower bound of the 95% confidence interval (CI) of the difference in SPR (PREHEVBRIO minus Engerix-B) was greater than -5%.
SPL UNCLASSIFIED SECTION
Study 1 in adults ≥18 years of age
The immunogenicity population included 718 subjects who received PREHEVBRIO and 723 subjects who received Engerix-B. The mean age was 57 years in both groups. The primary analysis compared the SPR, 4 weeks after receiving the third dose of PREHEVBRIO or Engerix-B in subjects ≥ 18 years of age. The SPR induced by PREHEVBRIO compared to Engerix-B was non-inferior in subjects ≥ 18 years of age ( Table 5).
| |||||
| |||||
| |||||
| |||||
| |||||
| |||||
| Study Population | PREHEVBRIO N | PREHEVBRIO SPR (95% CI) | Engerix-B N | Engerix-B SPR (95% CI) | Difference in SPR; PREHEVBRIO – Engerix-B (95% CI) |
| All Adults (Age 18+) a | 718 | 91.4 (89.1, 93.3) | 723 | 76.5 (73.2, 79.5) | 14.9 (11.2, 18.6) c |
| Age 45+ b | 625 | 89.4 (86.8, 91.7) | 627 | 73.1 (69.4, 76.5) | 16.4 (12.2, 20.7) d |
| Age 18-44 | 125 | 99.2 (95.6, 100.0) | 135 | 91.1 (85.0. 95.3) | - e |
| Age 45-64 | 325 | 94.8 (91.8, 96.6) | 322 | 80.1 (75.3, 84.3) | - e |
| Age 65 + | 268 | 83.6 (78.6, 87.8) | 266 | 64.7 (58.6, 70.4) | - e |
SPL UNCLASSIFIED SECTION
Study 2 in adults 18 through 45 years of age
The immunogenicity population included 1,753 subjects who received PREHEVBRIO and 592 subjects who received Engerix-B. The mean age was 34 years in the PREHEVBRIO group and 33 years in the Engerix-B group. The study compared the SPR, 4 weeks after receiving the third dose of PREHEVBRIO or Engerix-B in all subjects. The SPR induced by PREHEVBRIO compared to Engerix-B was non-inferior ( Table 6).
| |||||
| |||||
| Study Population | PREHEVBRIO N | PREHEVBRIO SPR (95% CI) | Engerix-B N | Engerix-B SPR (95% CI) | Difference in SPR; PREHEVBRIO –Engerix-B (95% CI) |
| Age 18-45 | 1753 | 99.3 (98.7. 99.6) | 592 | 94.8 (92.7, 96.4) | 4.5 (2.9, 6.6) * |
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Single dose vial, 1.0 mL (NDC number 75052-001-01)
Supplied as a package of 10 single dose vials (NDC number: 75052-001-10)
The vial stoppers are not made with natural rubber latex.
16.2 Storage Conditions
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light.
Do not freeze; discard if the vaccine has been frozen.
Do not use the vaccine after the expiration date shown on the vial label.
17 PATIENT COUNSELING INFORMATION
- Inform vaccine recipient of the potential benefits and risks associated with vaccination with PREHEVBRIO, as well as the importance of completing the immunization series.
- Emphasize that PREHEVBRIO contains non-infectious purified HBsAg and cannot cause hepatitis B infection.
- Advise vaccine recipient to report any adverse events to their healthcare provider or to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 and www.vaers.hhs.gov.
- Provide the Vaccine Information Statements, which are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).
Manufactured by: VBI Vaccines Inc.
160 Second St., 3rd Floor, Cambridge, MA, USA, 02142
U.S. License No. 2219
©2021 VBI Vaccines. All rights reserved.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Principal Display Panel - 10 mcg/mL Carton Label
NDC 75052-001-10
Hepatitis B Vaccine
(Recombinant)
PreHevbrio
Rx only
For adults 18 years or older
10
mcg/mL
10 x 1 mL
single-dose vials
For
intramuscular
administration
VBI
VACCINES
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Principal Display Panel - 10 mcg/mL Vial Label
NDC 75052-001-01
Hepatitis B Vaccine
(Recombinant)
PreHevbrio
For IM administration
Rx only
Storage:
2°C to 8°C
1
Dose
(1 mL)
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 2588237 | Hepatitis B (Recombinant) Vaccine 1 ML Injection | PSN | 6 |
| 2588240 | PREHEVBRIO Hepatitis B (Recombinant) Vaccine 1 ML Injection | PSN | 6 |
| 2588240 | 1 ML hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection [Prehevbrio] | SBD | 6 |
| 2588237 | 1 ML hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection | SCD | 6 |
| 2588240 | Prehevbrio vaccine 1 ML Injection | SY | 6 |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 75052-001-10 | 2025-07-29 | C162847 | 48780-1 | 3b156c62-312a-fb37-e063-e6dba90a4e07 | These highlights do not include all the information needed to use PREHEVBRIO TM safely and effectively. See full prescribing information for PREHEVBRIO. PREHEVBRIO [Hepatitis B Vaccine (Recombinant)] Injectable suspension, for intramuscular use Initial U.S. Approval: 2021 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 75052-001-01 | PREHEVBRIO | 1 mL in 1 VIAL, GLASS | INJECTION, SUSPENSION | 1 | 6 | |
| 75052-001-10 | PREHEVBRIO | 10 in 1 CARTON | INJECTION, SUSPENSION | 10 | 6 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 75052-001-01 | ML - Milliliter | 75052-001 | b0c8c71c-c3f9-46ff-a3c5-52c3e2eca772 | 1 | 2022-02-07 |
| 75052-001-10 | ML - Milliliter | 75052-001 | 893b43ad-57c5-4d07-badb-8347f8ac3adf | 1 | 2022-02-07 |
Products#
Every source-derived product name is available through these pages.
- PREHEVBRIO
- Hepatitis B Vaccine (Recombinant)
- SODIUM CHLORIDE
- POTASSIUM CHLORIDE
- SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE
- MONOBASIC POTASSIUM PHOSPHATE
- SODIUM HYDROXIDE
- HYDROCHLORIC ACID
- ALUMINUM HYDROXIDE
- WATER
- RECOMBINANT HEPATITIS B SURFACE ANTIGEN (ISOFORM S)
- RECOMBINANT HEPATITIS B SURFACE ANTIGEN (ISOFORM M)
- RECOMBINANT HEPATITIS B SURFACE ANTIGEN (ISOFORM L)
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 75052-001 | 75052-001-01, 75052-001-10 |
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125737 | Prehevbrio | Hepatitis B Vaccine (Recombinant) | 351(a) | Disc | 2026-09-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nacl 0.9% Normal Saline Solution | SODIUM CHLORIDE | CHI FUNG TECHNOLOGY COMPANY | 5a53c4c8-c9de-700c-e063-6394a90a3ab5 | 2026-08-31 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | YYBA CORP | 597f3347-647c-3545-e063-6294a90abab2 | 2026-08-20 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Kabi USA, LLC | 2e5fe9f4-78e5-4af4-8bf9-9680e5dc5e88 | 2026-08-20 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Hypertonic Saline | SODIUM CHLORIDE | NAVEH PHARMA (1996) LTD | 167c7a9c-1228-4fb2-a89c-d3e148386323 | 2026-07-30 | Warnings | SODIUM CHLORIDE |
| Hypertonic Saline Solution Sodium Chloride | SODIUM CHLORIDE | NAVEH PHARMA (1996) LTD | 750ea4b1-de2b-4299-aaa2-331daf383d0d | 2026-07-30 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Medical Care de Mexico, S.A. de C.V. | 9a1220fb-6853-45ae-838c-10d8596e1af7 | 2026-07-27 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Medical Care Renal Therapies Group, LLC | af5cdf1a-19f4-11e2-892e-0800200c9a66 | 2026-07-27 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | LABORATORIOS GRIFOLS SA | eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf | 2026-07-15 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| WHWSWB 0.9% Saline | SODIUM CHLORIDE | Yiwu Huanshu E-commerce Co., Ltd | 4e9c21e5-f2f9-90e4-e063-6394a90acfe2 | 2026-07-11 | Warnings | SODIUM CHLORIDE |
| WHWSWB 0.9% SALINE | SODIUM CHLORIDE | Yiwu Huanshu E-commerce Co., Ltd | 5082b773-79b2-2501-e063-6394a90a170f | 2026-07-11 | Warnings | SODIUM CHLORIDE |
| SALINE NASAL | SODIUM CHLORIDE | ALAINA HEALTHCARE PRIVATE LIMITED | ed30a7f9-7132-42da-9bed-63a9b1c80ab2 | 2026-07-07 | Warnings | SODIUM CHLORIDE |
| OHTrust Artifical Eyedrop | SODIUM CHLORIDE | Nanoplus Technology Co., Limited | 2ea26d96-704b-17bb-e063-6394a90a7e27 | 2026-07-01 | Warnings | SODIUM CHLORIDE |
| 0.9% Sodium Chloride Saline Solution | SODIUM CHLORIDE | Yunqi Cosmetics (Shenzhen) Co., Ltd | 546af257-dbd1-11fc-e063-6394a90a8e0a | 2026-06-16 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Cardinal Health 107, LLC | 107af8bc-b6af-4b85-8c8a-ea757dcef1da | 2026-06-12 | Adverse reactions | SODIUM CHLORIDE |
| SALINE CLEANING | SODIUM CHLORIDE | Guangzhou Huanmei Cosmetics Co., Ltd. | 524f07cc-ddb9-dda5-e063-6394a90ac0a5 | 2026-05-21 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Hospira, Inc. | a2a964f7-c3ec-4dfb-e3a0-6d8136a80397 | 2026-05-19 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Sportpharm LLC | a2c111f6-74d5-4a5d-82ac-d0f237488cb8 | 2026-04-24 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Method Pharmaceuticals, LLC | 4b08859e-65bd-8255-e063-6394a90af614 | 2026-04-23 | Warnings | SODIUM CHLORIDE |
| SODIUM CHLORIDE 1 GRAM | SODIUM CHLORIDE | Gendose Pharmaceuticals, LLC | ce988ae5-61c6-4324-90e1-a94c8a54d0d0 | 2026-04-13 | Warnings | SODIUM CHLORIDE |
| Walgreens Sodium Chloride Ophthalmic 5 Percent Hypertonicity Eye | SODIUM CHLORIDE | Walgreen Company | bda3b9db-5fc4-408c-a5ae-d1eeb3ee308d | 2026-04-06 | Warnings | SODIUM CHLORIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.